ATP acts as an agonist to promote stimulus-induced secretion of IL-1 beta and IL-18 in human blood.
Cultured monocytes and macrophages stimulated with LPS produce large quantities of proIL-1beta, but release little mature cytokine to the medium. The efficiency at which the procytokine is converted to its active 17-kDa species and released extracellularly is enhanced by treating cytokine-producing cells with a secretion stimulus such as ATP or nigericin. To determine whether this need for a secretion stimulus extends to blood, individual donors were bled twice daily for 4 consecutive days, and the collected blood samples were subjected to a two-step IL-1 production assay. LPS-activated blood samples generated cell-free IL-1beta, but levels of the extracellular cytokine were greatly increased by subsequent treatment with ATP or nigericin. Specificity and concentration requirements of the nucleotide triphosphate effect suggests a P2X(7) receptor involvement. Quantities of IL-1beta generated by an individual donor's blood in response to the LPS-only and LPS/ATP stimuli were relatively consistent over the 4-day period. Between donors, consistent differences in cytokine production capacity were observed. Blood samples treated with ATP also demonstrated enhanced IL-18 production, but TNF-alpha levels decreased. Among leukocytes, monocytes appeared to be the most affected cellular targets of the ATP stimulus. These studies indicate that an exogenous stimulus is required by blood for the efficient production of IL-1beta and IL-18, and suggest that circulating blood monocytes constitutively express a P2X(7)-like receptor.
Perregaux
D G
DG
Department of Respiratory, Allergy, Immunology, Inflammation, and Infectious Diseases, Pfizer Central Research, Groton, CT 06340, USA.
McNiff
P
P
Laliberte
R
R
Conklyn
M
M
Gabel
C A
CA
D000255:Adenosine Triphosphate / Q000819:agonists* / Q000097:blood; D000276:Adjuvants, Immunologic / Q000819:agonists / Q000097:blood; D001172:Arthritis, Rheumatoid / Q000097:blood / Q000276:immunology; D002940:Circadian Rhythm / Q000276:immunology; D004804:Eosinophils / Q000276:immunology / Q000378:metabolism; D005260:Female; D006801:Humans; D007375:Interleukin-1 / Q000096:biosynthesis / Q000097:blood* / Q000378:metabolism*; D020382:Interleukin-18 / Q000097:blood* / Q000378:metabolism*; D008070:Lipopolysaccharides / Q000097:blood / Q000494:pharmacology; D008213:Lymphocyte Activation; D008214:Lymphocytes / Q000276:immunology / Q000378:metabolism; D008297:Male; D009000:Monocytes / Q000276:immunology / Q000378:metabolism; D018375:Neutrophil Activation / Q000276:immunology; D009504:Neutrophils / Q000276:immunology / Q000378:metabolism; D011499:Protein Processing, Post-Translational / Q000276:immunology; D018048:Receptors, Purinergic P2 / Q000096:biosynthesis; D058486:Receptors, Purinergic P2X7
D000276:Adjuvants, Immunologic; D007375:Interleukin-1; D020382:Interleukin-18; D008070:Lipopolysaccharides; C546468:P2RX7 protein, human; D018048:Receptors, Purinergic P2; D058486:Receptors, Purinergic P2X7; D000255:Adenosine Triphosphate